King Pharmaceuticals

Last updated
King Pharmaceuticals, Inc.
Company type Subsidiary
Industry Pharmaceutical company, health care
Founded1994;30 years ago (1994)
Headquarters Bristol, Tennessee, U.S.
Key people
Brian Markison (CEO)
Joseph Squicciarino (CFO)
Eric J. Bruce (CTO)
Products Pharmaceuticals
Revenue$1.7 billion USD (2009) [1]
$236 million USD (2009) [1]
$92 million USD (2009) [1]
Number of employees
3,381
Parent Pfizer
Website kingpharm.com

King Pharmaceuticals, Inc. is a pharmaceutical company, a wholly owned subsidiary of Pfizer based in Bristol, Tennessee. Before being acquired by Pfizer, it was the world's 39th largest pharmaceutical company. [1] [2] On October 12, 2010, King was acquired by Pfizer for $14.25 per share. [3] King produced a wide range of pharmaceuticals, including Altace for heart attack prevention, Levoxyl for hypothyroidism, Sonata, a sleeping aid, and Skelaxin, a muscle relaxant. King Pharmaceuticals operated manufacturing facilities in Bristol, Tennessee; Rochester, Michigan; St. Louis, Missouri; St. Petersburg, Florida; and Middleton, Wisconsin. They employed approximately 2,700 people including a sales force of over 1,000 individuals.

Contents

King Pharmaceuticals, Inc. was incorporated in the State of Tennessee in 1993. According to the King Pharmaceutcals, Inc. Form 10-K for the year ended December 31, 2007 filed with the U.S. Securities and Exchange Commission, the wholly owned subsidiaries of King Pharmaceuticals, Inc. are Monarch Pharmaceuticals, Inc.; King Pharmaceuticals Research and Development, Inc.; Meridian Medical Technologies, Inc.; Parkedale Pharmaceuticals, Inc.; King Pharmaceuticals Canada Inc.; and Monarch Pharmaceuticals Ireland Limited. [4]

Company history

King Pharmaceuticals was founded in 1993 John M. Gregory, Randal J. Kirk, Joseph "Joe" R. Gregory, Jefferson "Jeff" J. Gregory, and James E. Gregory. [5] [6] In January 1994, King acquired a former King College campus plant in Bristol, Tennessee. The 500,000-square-foot (46,000 m2) facility was purchased for $1.18 million from RSR Pharmaceutical, who had been using it after Beecham merged with SmithKline. King initially manufactured drugs for other pharmaceutical companies, but soon established a strategy of acquiring branded prescription drugs, which have a much higher gross margin than contract manufactured drugs.

In February 1998, King acquired 15 branded pharmaceuticals, a sterile products manufacturing facility located in Rochester, Michigan that it called the "Parkedale Facility") and some contract manufacturing contracts. [7] By December 1998 King had placed its sterile products business into a subsidiary it named Parkedale Pharmaceuticals. [8]

King Pharmaceuticals obtained about twenty smaller branded drugs from the start up of the company until it went public in June 1998. The King Pharmaceuticals subsidiary Monarch Pharmaceuticals acquired one of its most profitable branded drugs, Altace, later the same year on December 18, 1998 from Hoechst Marion Roussel.

U.S. marketing and distribution rights to Altace

Hoechst merged with Marion Merrill Dow of Kansas City, Missouri in 1995, forming the Hoechst U.S. pharmaceutical subsidiary Hoechst Marion Roussel (HMR). Altace was bringing in under $90 million in U.S. revenues for HMR and Hoechst had stopped promoting Altace within the United States., [9] and King Pharmaceuticals President Jefferson "Jeff" Gregory also began negotiations in 1995 with Hoechst to acquire U.S. distribution rights to Altace. [9]

The King Pharmaceuticals wholly owned subsidiary Monarch Pharmaceuticals, Inc. (another brother of John Gregory - Joseph Gregory - was then the president of Monarch Pharmaceuticals) acquired ownership of the U.S. distribution and marketing rights to Altace and other Hoechst products from Hoechst AG subsidiary Hoechst Marion Roussel of Kansas City, Missouri on December 18, 1998, and [10] following a January 1999 merger a few weeks later with Rhône-Poulenc, Hoechst assumed the new corporate identity of Aventis).

In 2001, Forbes magazine ranked John Gregory among the 400 richest Americans. The bulk of Gregory's personal fortune was due in large part due to the ability of King Pharmaceuticals, Inc. to reintroduce the Hoechst branded prescription drug Altace back into the U.S. market under the King Pharmaceuticals, Inc. subsidiary Monarch Pharmaceuticals brand following the 1998 U.S. marketing and distribution agreement between King Pharmaceuticals/Monarch Pharmaceuticals and Hoechst AG/HMR.

In late December 1998, King Pharmaceuticals (d.b.a. Monarch Pharmaceuticals, Inc.) purchased the U.S. marketing and distribution rights of the company's most successful drug, Altace, for $362.5 million from the U.S. subsidiary of Hoechst AG, Hoechst Marion Roussel of Kansas City. [11] As a result of increasing the number of sales representatives and the findings of the Heart Outcomes Prevention Evaluation (HOPE), [12] Altace sales increased. Using profits from Altace, King continued to add product lines, the most significant purchases being Levoxyl, Thrombin, and Cytomel in 2000.[ citation needed ] Also in 2000, seeing fewer opportunities to obtain branded drugs, the company acquired an R&D company based in North Carolina.[ citation needed ] In 2002, King and Meridian Medical Technologies agreed that King would purchase Merdian for $247.8 million in cash; Meridian was a manufacturer of autoinjectors, including EpiPen, an epinephrine autoinjector. [13] The deal was completed in January 2003. [14]

In 2002, John Gregory stepped down as CEO, and his brother Jefferson Gregory took over. Then in 2004, Jeff Gregory stepped down as well after the SEC began investigations into King's Medicaid billing practices. [15] The board named Brian Markison to replace him. Soon after, in July 2004, a deal was made for Mylan Laboratories to acquire King for $4 billion. [16] Investors, most notably Carl Icahn, were critical of the merger, saying that Mylan was overpaying for King. The next year the deal was called off.

In 2008 King Pharmaceuticals acquired Alpharma Pharmaceuticals to expand into the pain treatment market. From the acquisition, King gained the patents on the pain management drugs, Flector and Embeda. [17] They also gained a completely separate animal health division, which focuses on the many agricultural and animal health needs of livestock animals.

Acquisition

On October 12, 2010, Pfizer Inc. (NYSE :  PFE) announced it would acquire Bristol-based King Pharmaceuticals, Inc. for a total cost to Pfizer of $3.6 billion in cash or $14.25 per share. The acquisition was expected to expand Pfizer's product line of pain relief and management medication by adding King products such as Embeda, Avinza, and the Flector Patch. [18] Other product lines that made King attractive to Pfizer included the EpiPen for emergency delivery of medications and the Alpharma animal health line. [19]

Related Research Articles

<span class="mw-page-title-main">Hoechst AG</span> German chemicals company

Hoechst AG was a German chemicals, later life sciences, company that became Aventis Deutschland after its merger with France's Rhône-Poulenc S.A. in 1999. With the new company's 2004 merger with Sanofi-Synthélabo, it became a subsidiary of the resulting Sanofi-Aventis pharmaceuticals group.

An epinephrine autoinjector is a medical device for injecting a measured dose or doses of epinephrine (adrenaline) by means of autoinjector technology. It is most often used for the treatment of anaphylaxis. The first epinephrine autoinjector was brought to market in 1983.

Sanofi S.A. is a French multinational pharmaceutical and healthcare company headquartered in Paris, France. The corporation was established in 1973 and merged with Synthélabo in 1999 to form Sanofi-Synthélabo. In 2004, Sanofi-Synthélabo merged with Aventis and renamed to Sanofi-Aventis, which were each the product of several previous mergers. It changed its name back to Sanofi in May 2011. The company is a component of the Euro Stoxx 50 stock market index. In 2023, the company’s seat in Forbes Global 2000 was 89.

Dr. Reddy's Laboratories is an Indian multinational pharmaceutical company based in Hyderabad. The company was founded by Kallam Anji Reddy, who previously worked in the mentor institute Indian Drugs and Pharmaceuticals Limited. Dr. Reddy manufactures and markets a wide range of pharmaceuticals in India and overseas. The company produces over 190 medications, 60 active pharmaceutical ingredients (APIs) for drug manufacture, diagnostic kits, critical care, and biotechnology.

<span class="mw-page-title-main">Biocon</span> Indian multinational biopharmaceutical company

Biocon Limited is an Indian biopharmaceutical company based in Bangalore. It was founded by Kiran Mazumdar-Shaw in 1978. The company manufactures generic active pharmaceutical ingredients (APIs) that are sold in approximately 120 countries, including the United States and Europe. It also manufactures novel biologics as well as biosimilar insulins and antibodies, which are sold in India as branded formulations. Biocon's biosimilar products are also sold in both bulk and formulation forms in several emerging markets.

<span class="mw-page-title-main">Roussel Uclaf</span> French pharmaceutical company

Roussel Uclaf S.A. was a French pharmaceutical company and one of several predecessor companies of today's Sanofi.

Mylan N.V. was a global generic and specialty pharmaceuticals company. In November 2020, Mylan merged with Upjohn, Pfizer's off-patent medicine division, to form Viatris. Previously, the company was domiciled in the Netherlands, with principal executive offices in Hatfield, Hertfordshire, UK and a "Global Center" in Canonsburg, Pennsylvania, US.

The pharmaceutical industry is one of the leading industries in the People's Republic of China, covering synthetic chemicals and drugs, prepared Chinese medicines, medical devices, apparatus and instruments, hygiene materials, packing materials, and pharmaceutical machinery. China has the second-largest pharmaceutical market in the world as of 2017 which is worth US$110 billion. China accounts for 20% of the world's population but only a small fraction of the global drug market. China's changing health-care environment is designed to extend basic health insurance to a larger portion of the population and give individuals greater access to products and services. Following the period of change, the pharmaceutical industry is expected to continue its expansion.

<span class="mw-page-title-main">Hospira</span> American pharmaceutical company

Hospira was an American global pharmaceutical and medical device company with headquarters in Lake Forest, Illinois. It had approximately 19,000 employees. Before its acquisition by Pfizer, Hospira was the world's largest producer of generic injectable pharmaceuticals, manufacturing generic acute-care and oncology injectables, as well as integrated infusion therapy and medication management systems. Hospira's products are used by hospitals and alternate site providers, such as clinics, home healthcare providers and long-term care facilities. It was formerly the hospital products division of Abbott Laboratories. On September 3, 2015, Hospira was acquired by Pfizer, who subsequently sold off the medical devices portion of Hospira to ICU Medical.

<span class="mw-page-title-main">Apotex</span> Canadian pharmaceutical company

Apotex Inc. is a Canadian pharmaceutical corporation. Founded in 1974 by Barry Sherman, the company is the largest producer of generic drugs in Canada, with annual sales exceeding CA$2.5 billion. By 2023, Apotex employed close to 8,000 people as Canada's largest drug manufacturer, with over 300 products selling in over 115 countries. Apotex manufactures and distributes generic medications for a range of diseases and health conditions that include cancer, diabetes, high cholesterol, glaucoma, infections and blood pressure.

<span class="mw-page-title-main">Teva Pharmaceuticals</span> Israeli pharmaceutical company

Teva Pharmaceutical Industries Ltd. is an Israeli multinational pharmaceutical company. Teva specializes primarily in generic drugs, but other business interests include branded-drugs, active pharmaceutical ingredients (API's) and, to a lesser extent, contract manufacturing services and an out-licensing platform.

John M. Gregory is an American businessman. He was former CEO of King Pharmaceuticals, Inc. and resides in Bristol, Tennessee. In addition to founding King Pharmaceuticals in 1993, Gregory has founded several other notable business ventures including SJ Strategic Investments and Leitner Pharmaceuticals. Gregory has also made major investment outside of the pharmaceutical industry, such as his investments within the privately held United Coal Company located in southwest Virginia and Adams Golf with U.S. corporate offices in Texas. Most recently, Gregory, along with other family members, began Gregory Pharmaceutical Holdings Inc. which include pharmaceutical contract manufacturing company, UPM Pharmaceuticals, and NFI Consumer Products which includes the Blue-Emu brand of products.

Marion Merrell Dow and its predecessor Marion Laboratories was a U.S. pharmaceutical company based in Kansas City, Missouri, from 1950 until 1996.

<span class="mw-page-title-main">Amneal Pharmaceuticals</span> American publicly traded generics and specialty pharmaceutical company

Amneal Pharmaceuticals, Inc. is an American publicly traded generics and specialty pharmaceutical company. The company is headquartered in Bridgewater, New Jersey.

Meridian Medical Technologies, LLC is an American company which specialized primarily in developing and manufacturing antidotes for chemical weapons.

Alvogen is an Icelandic pharmaceutical company founded in 2009. In 2014, a controlling stake in the company was acquired by CVC Capital Partners and Temasek Holdings. Alvogen has about 350 different medical and non-medical products, and both produces its own products and markets the products of brand name pharmaceutical companies.

Viatris Inc. is an American global pharmaceutical and healthcare corporation headquartered in Canonsburg, Pennsylvania. The corporation was formed through the merger of Mylan and Upjohn, a legacy division of Pfizer, on November 16, 2020.

References

  1. 1 2 3 4 "Pfizer: One of the world's premier biopharmaceutical companies". www.pfizer.com.
  2. ↑ "Pharmaceutical Executive - 2006 Top 50 Pharmaceutical Companies" (PDF). Archived from the original (PDF) on 2011-07-11. Retrieved 2007-12-20.
  3. ↑ "Pfizer to Buy King Pharmaceuticals for $3.6 Billion". The New York Times. October 12, 2010.
  4. ↑ "King Pharmaceuticals, Inc. Form 10-K, Annual report for the fiscal year ended December 31, 2007". SEC Edgar.
  5. ↑ "History of King Pharmaceuticals, Inc. – FundingUniverse". www.fundinguniverse.com.
  6. ↑ https://web.archive.org/web/20030201091134/http://www.kingpharm.com/chairman.htm King Pharmaceuticals, Inc. - Message From Our Chairman.
  7. ↑ "King Pharmaceuticals, Amendment 8 to Form S-1". NASDAQ. June 2, 1988.
  8. ↑ "Press Release: King Pharmaceuticals and Hoechst Marion Roussel Sign an Agreement for One Of The Largest Single Product Transactions in Emerging Pharmaceutical Sector | Evaluate". King, via Evaluate. December 18, 1998.
  9. 1 2 "Faith Healers: The born-again Gregory brothers worked a financial miracle from cast-off drug brands". Forbes. Zina Moukheiber. October 28, 2002.
  10. ↑ "Monarch Pharmaceuticals acquired" Archived 2016-03-03 at the Wayback Machine . sanofi-aventis Group. December 18, 1998.
  11. ↑ http://archive.twst.com/notes/articles/jab202.html Archived 2009-02-10 at the Wayback Machine "King Pharmaceuticals CEO focuses on patented products".
  12. ↑ HOPE
  13. ↑ King Pharmaceuticals Oct 21, 2002. Press Release: King Pharmaceuticals to Acquire Meridian Medical Technologies Archived 2016-08-26 at the Wayback Machine
  14. ↑ King Pharmaceuticals Form 11K filed For the fiscal year ended December 31, 2003.
  15. ↑ "TheStreet.com : King Pharmaceuticals CEO to Step Down - Robert Steyer - KG". Archived from the original on 2004-09-23. Retrieved 2007-12-20.
  16. ↑ Abboud, Leila; Berman, Dennis K. (July 26, 2004). "Mylan to Buy King Pharmaceuticals". The Wall Street Journal.
  17. ↑ King Pharmaceuticals Acquires Alpharma
  18. ↑ "Pfizer: One of the world's premier biopharmaceutical companies". www.pfizer.com.
  19. ↑ "Pfizer Completes Acquisition Of King Pharmaceuticals, Inc.; Pfizer and King begin joint operations on March 1, 2011" (press release). Pfizer. March 1, 2011. Archived from the original on June 30, 2013.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.